Evidence Snapshot

Non-receptor tyrosine-protein kinase TYK2

CHEMBL3553 SINGLE PROTEIN Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:51:04Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 4:51 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL3553

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Non-receptor tyrosine-protein kinase TYK2 as ChEMBL target CHEMBL3553, mapped to UniProt P29597. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Non-receptor tyrosine-protein kinase TYK2

SINGLE PROTEIN · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL3553

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

P29597

Non-receptor tyrosine-protein kinase TYK2

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Non-receptor tyrosine-protein kinase TYK2 matters

As of 2026-09-13

Non-receptor tyrosine-protein kinase TYK2 is reviewed as Non-receptor tyrosine-protein kinase TYK2 (UniProt P29597); Non-receptor tyrosine-protein kinase TYK2 shows approved-linked disease relevance led by alopecia areata. 5 more disease programs remain visible in the same review block.; 3 linked drugs keep this evidence frame grounded.; the current evidence base includes 42 approved drugs, 10420 compounds, and 889 assays, with lead potency reaching pChEMBL 11.0.

Protein context

Non-receptor tyrosine-protein kinase TYK2

Non-receptor tyrosine-protein kinase TYK2 Sequence length is 1187 aa.

Review this target as Non-receptor tyrosine-protein kinase TYK2, mapped to UniProt P29597. Sequence length is 1187 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt P29597 Protein

Disease context

alopecia areata

Non-receptor tyrosine-protein kinase TYK2 shows approved-linked disease relevance led by alopecia areata. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include BREPOCITINIB, DEUCRAVACITINIB, DEURUXOLITINIB PHOSPHATE.

Start review with alopecia areata because it currently carries approved-linked support. Linked drugs include BREPOCITINIB, DEUCRAVACITINIB, DEURUXOLITINIB PHOSPHATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Approved-linked 3 linked drugs

Activity base

Portfolio and assay base

ChEMBL currently tracks 42 approved drugs, 10420 compounds, and 889 assays for this target. The dominant activity type is KD. CHEMBL5427107 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL5427107 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine

42 approved pChEMBL 11.0

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Non-receptor tyrosine-protein kinase TYK2 matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P29597, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why alopecia areata is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

10420

Total Compounds

889

Total Assays

Approved Drugs

IC50: 6307.0, KI: 2745.0, EC50: 304.0, KD: 7823.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL5427107	11.0	IC50	—
No preferred name CHEMBL4460368	10.8	Ki	—
No preferred name CHEMBL5427277	10.8	IC50	—
No preferred name CHEMBL4442827	10.7	Ki	—
No preferred name CHEMBL5422022	10.7	IC50	—

Approved Drugs

Structure	Compound	First Approval
	MOMELOTINIB CHEMBL1078178	2023
	CRAVACITINIB CHEMBL4596392	2022
	DEUCRAVACITINIB CHEMBL4435170	2022
	PACRITINIB CHEMBL2035187	2022
	ABROCITINIB CHEMBL3655081	2021
	FILGOTINIB CHEMBL3301607	2020
	FEDRATINIB CHEMBL1287853	2019
	UPADACITINIB CHEMBL3622821	2019
	PEFICITINIB CHEMBL3137308	2019
	BARICITINIB CHEMBL2105759	2017
	MIDOSTAURIN CHEMBL608533	2017
	NINTEDANIB CHEMBL502835	2014
	TOFACITINIB CHEMBL221959	2012
	TOFACITINIB CITRATE CHEMBL2103743	2012
	RUXOLITINIB PHOSPHATE CHEMBL1795071	2011
	RUXOLITINIB CHEMBL1789941	2011
	CRIZOTINIB CHEMBL601719	2011
	SUNITINIB CHEMBL535	2006
	DASATINIB CHEMBL5416410	2006

← Target Page

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:51:04Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 4:51 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL3553